Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis.

Ghosh A, Sarkar S, Banerjee S, Behbod F, Tawfik O, McGregor D, Graff S, Banerjee SK.

PLoS One. 2018 May 29;13(5):e0198143. doi: 10.1371/journal.pone.0198143. eCollection 2018.

2.

Chemokine Signaling Facilitates Early-Stage Breast Cancer Survival and Invasion through Fibroblast-Dependent Mechanisms.

Brummer G, Acevedo DS, Hu Q, Portsche M, Fang WB, Yao M, Zinda B, Myers M, Alvarez N, Fields P, Hong Y, Behbod F, Cheng N.

Mol Cancer Res. 2018 Feb;16(2):296-308. doi: 10.1158/1541-7786.MCR-17-0308. Epub 2017 Nov 13.

PMID:
29133591
3.

Whole Mammary Gland Transplantation in Mice Protocol.

Hansford H, Hong Y, Kittrell F, Medina D, Behbod F.

Bio Protoc. 2017 Jun 5;7(11). pii: e2326. doi: 10.21769/BioProtoc.2326.

4.

NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.

Elsarraj HS, Valdez KE, Hong Y, Grimm SL, Ricci LR, Fan F, Tawfik O, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Hilsenbeck S, Edwards DP, Hagan CR, Godwin AK, Fabian C, Behbod F.

Cancer Res. 2017 Jul 15;77(14):3802-3813. doi: 10.1158/0008-5472.CAN-16-2794. Epub 2017 May 17.

5.

IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.

Lui AJ, Geanes ES, Ogony J, Behbod F, Marquess J, Valdez K, Jewell W, Tawfik O, Lewis-Wambi J.

Cancer Lett. 2017 Jul 28;399:29-43. doi: 10.1016/j.canlet.2017.04.005. Epub 2017 Apr 12.

6.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

7.

TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway.

Su X, Napoli M, Abbas HA, Venkatanarayan A, Bui NHB, Coarfa C, Gi YJ, Kittrell F, Gunaratne PH, Medina D, Rosen JM, Behbod F, Flores ER.

Oncogene. 2017 Apr 27;36(17):2377-2393. doi: 10.1038/onc.2016.388. Epub 2016 Nov 21.

8.

Mouse Mammary Intraductal (MIND) Method for Transplantation of Patient Derived Primary DCIS Cells and Cell Lines.

Kittrell F, Valdez K, Elsarraj H, Hong Y, Medina D, Behbod F.

Bio Protoc. 2016 Mar 5;6(5). pii: e1744.

9.

Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression.

Chang CC, Zhang C, Zhang Q, Sahin O, Wang H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, Hung MC, Behbod F, Yu D.

Oncotarget. 2016 Jun 7;7(23):35270-83. doi: 10.18632/oncotarget.9136.

10.

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.

11.

Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.

Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF.

BMC Cancer. 2015 Aug 13;15:584. doi: 10.1186/s12885-015-1576-3.

12.

Side population.

Behbod F, Vivanco MD.

Methods Mol Biol. 2015;1293:73-81. doi: 10.1007/978-1-4939-2519-3_4. Review.

PMID:
26040682
13.

Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.

Zou A, Lambert D, Yeh H, Yasukawa K, Behbod F, Fan F, Cheng N.

BMC Cancer. 2014 Oct 24;14:781. doi: 10.1186/1471-2407-14-781.

14.

A novel role of microRNA146b in promoting mammary alveolar progenitor cell maintenance.

Elsarraj HS, Hong Y, Valdez K, Carletti M, Salah SM, Raimo M, Taverna D, Prochasson P, Bharadwaj U, Tweardy DJ, Christenson LK, Behbod F.

J Cell Sci. 2013 Jun 1;126(Pt 11):2446-58. doi: 10.1242/jcs.119214. Epub 2013 Apr 9.

15.

The Zero-truncated Poisson with Right Censoring: an Application to Translational Breast Cancer Research.

Yeh HW, Gajewski B, Mukhopadhyay P, Behbod F.

Stat Biopharm Res. 2012 Aug 30;4(3):252-263.

16.

An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer.

Li H, Duhachek-Muggy S, Qi Y, Hong Y, Behbod F, Zolkiewska A.

Breast Cancer Res Treat. 2012 Oct;135(3):759-69. doi: 10.1007/s10549-012-2220-4. Epub 2012 Aug 29.

17.

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.

Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.

18.

Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).

Scribner KC, Behbod F, Porter WW.

Oncogene. 2013 May 23;32(21):2631-9. doi: 10.1038/onc.2012.286. Epub 2012 Jul 9.

19.

Overactivation of Ras signaling pathway in CD133+ MPNST cells.

Borrego-Diaz E, Terai K, Lialyte K, Wise AL, Esfandyari T, Behbod F, Mautner VF, Spyra M, Taylor S, Parada LF, Upadhyaya M, Farassati F.

J Neurooncol. 2012 Jul;108(3):423-34. doi: 10.1007/s11060-012-0852-1. Epub 2012 Apr 8.

PMID:
22484909
20.

Mammary gland development & breast cancer; connecting the dots by non-coding RNAs.

Behbod F, Rosen JM.

J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):1-2. doi: 10.1007/s10911-012-9248-2. No abstract available.

21.

Emerging functions of microRNA-146a/b in development and breast cancer: microRNA-146a/b in development and breast cancer.

Elsarraj HS, Stecklein SR, Valdez K, Behbod F.

J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):79-87. doi: 10.1007/s10911-012-9240-x. Epub 2012 Feb 19.

PMID:
22350993
22.

Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F.

J Pathol. 2011 Dec;225(4):565-73. doi: 10.1002/path.2969. Epub 2011 Sep 26.

23.

Prospective isolation and characterization of committed and multipotent progenitors from immortalized mouse mammary epithelial cells with morphogenic potential.

Kittrell FS, Carletti MZ, Kerbawy S, Heestand J, Xian W, Zhang M, Lamarca HL, Sonnenberg A, Rosen JM, Medina D, Behbod F.

Breast Cancer Res. 2011 Apr 5;13(2):R41. doi: 10.1186/bcr2863.

24.

Immortalized, pre-malignant epithelial cell populations contain long-lived, label-retaining cells that asymmetrically divide and retain their template DNA.

Bussard KM, Boulanger CA, Kittrell FS, Behbod F, Medina D, Smith GH.

Breast Cancer Res. 2010;12(5):R86. doi: 10.1186/bcr2754. Epub 2010 Oct 21.

25.

Targeting the perpetrator: breast cancer stem cell therapeutics.

Pal A, Valdez KE, Carletti MZ, Behbod F.

Curr Drug Targets. 2010 Sep;11(9):1147-56. Review.

26.

CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland.

LaMarca HL, Visbal AP, Creighton CJ, Liu H, Zhang Y, Behbod F, Rosen JM.

Stem Cells. 2010 Mar 31;28(3):535-44. doi: 10.1002/stem.297.

27.

An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.

Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D.

Breast Cancer Res. 2009;11(5):R66. doi: 10.1186/bcr2358.

28.

Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.

Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM.

Cancer Res. 2008 Jun 15;68(12):4674-82. doi: 10.1158/0008-5472.CAN-07-6353.

29.

Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line.

Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA, Rosen JM.

J Cell Sci. 2007 Feb 1;120(Pt 3):468-77. Epub 2007 Jan 16.

30.

WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells.

Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM.

Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23. Epub 2007 Jan 3. Erratum in: Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7307.

31.

Transcriptional profiling of mammary gland side population cells.

Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM.

Stem Cells. 2006 Apr;24(4):1065-74. Epub 2005 Nov 10.

32.

On mammary stem cells.

Woodward WA, Chen MS, Behbod F, Rosen JM.

J Cell Sci. 2005 Aug 15;118(Pt 16):3585-94. Review.

33.

Will cancer stem cells provide new therapeutic targets?

Behbod F, Rosen JM.

Carcinogenesis. 2005 Apr;26(4):703-11. Epub 2004 Sep 30. Review.

PMID:
15459022
34.

Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells.

Behbod F, Nagy ZS, Stepkowski SM, Karras J, Johnson CR, Jarvis WD, Kirken RA.

J Immunol. 2003 Oct 15;171(8):3919-27.

35.

Isolation and characterization of functional mammary gland stem cells.

Welm B, Behbod F, Goodell MA, Rosen JM.

Cell Prolif. 2003 Oct;36 Suppl 1:17-32. Review.

36.

Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.

Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA.

Blood. 2002 Jan 15;99(2):680-9.

37.

PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection.

Stepkowski SM, Nagy ZS, Wang ME, Behbod F, Erwin-Cohen R, Kahan BD, Kirken RA.

Transplant Proc. 2001 Nov-Dec;33(7-8):3272-3. No abstract available.

PMID:
11750401
39.

Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection.

Wang M, Kirken R, Behbod F, Erwin-Cohen R, Stepkowski SM, Kahan BD.

Transplant Proc. 2001 Feb-Mar;33(1-2):201. No abstract available.

PMID:
11266779
40.

Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts.

Kirken RA, Erwin-Cohen R, Behbod F, Wang M, Stepkowski SM, Kahan BD.

Transplant Proc. 2001 Feb-Mar;33(1-2):95. No abstract available.

PMID:
11266723
41.

Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.

Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, Verani R, Kahan BD, Stepkowski SM, Kirken RA.

J Immunol. 2001 Mar 15;166(6):3724-32.

42.

Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells.

Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle F, Farrar WL.

J Leukoc Biol. 1999 Jun;65(6):891-9.

PMID:
10380915
43.

An activity in rat tissues that modifies nitrotyrosine-containing proteins.

Kamisaki Y, Wada K, Bian K, Balabanli B, Davis K, Martin E, Behbod F, Lee YC, Murad F.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11584-9.

44.

Sirolimus, a new, potent immunosuppressive agent.

Kelly PA, Gruber SA, Behbod F, Kahan BD.

Pharmacotherapy. 1997 Nov-Dec;17(6):1148-56. Review.

PMID:
9399599

Supplemental Content

Loading ...
Support Center